Liraglutide Use in Non-Diabetic Patients for Weight Management

Regulatory Approval and Clinical Indications

The American Gastroenterological Association (AGA) provides a conditional recommendation (moderate quality evidence) for using liraglutide 3.0 mg with lifestyle modifications in adults with obesity or overweight with weight-related complications who have had inadequate response to lifestyle interventions alone 1
Liraglutide 3.0 mg was FDA-approved in 2014 specifically for weight management in non-diabetic patients with obesity or overweight with weight-related complications, making it distinct from the lower-dose formulation (1.8 mg) used for diabetes 2, 3

Initiate at 0.6 mg subcutaneous injection daily for 1 week, then increase by 0.6 mg weekly until reaching the target dose of 3.0 mg daily 2, 3
Discontinue liraglutide if the patient has not achieved at least 4% weight loss after 16 weeks of treatment at the 3.0 mg dose 2, 3

Liraglutide has been associated with increased risk of pancreatitis and gallbladder disease, requiring patient counseling about symptoms 1
Delayed gastric emptying is a significant effect that persists even with chronic use, which has implications for aspiration risk during anesthesia and should be considered in perioperative planning 4

Liraglutide promotes weight loss through multiple mechanisms independent of glucose-lowering effects: activation of GLP-1 receptors in the hypothalamus and brainstem to suppress appetite and increase satiety, delayed gastric emptying leading to prolonged fullness, and reduction in caloric intake through central nervous system effects 3, 4

The American College of Cardiology is not mentioned in this article, however, the American Gastroenterological Association and the American Diabetes Association provide recommendations for liraglutide use, with the American Diabetes Association reporting that liraglutide produces 5.8-8.0% weight loss when used as an adjunct to lifestyle modifications, although no citation is provided for this specific fact, other facts are cited as follows:
Victoza (liraglutide) is used off-label for obesity, but health insurance coverage may be restricted to FDA-approved indications, with the 3.0 mg formulation (Saxenda) being the FDA-approved product for weight management in non-diabetics, with an average wholesale price approximately $1,385 per month for the maintenance dose 5, 6
Medicare currently excludes coverage of FDA-approved antiobesity medications for a diagnosis of obesity alone, and global shortages of GLP-1 receptor agonists currently exist 5, 6

Average wholesale price approximately $1,385 per month for the maintenance dose, with Medicare currently excluding coverage of FDA-approved antiobesity medications for a diagnosis of obesity alone 5, 6
Global shortages of GLP-1 receptor agonists currently exist 5, 6